Abstract
Background: Esophageal adenocarcinoma (EA) arises from Barrett’s epithelium (BE), and chronic gastroesophageal reflux disease is considered the strongest risk factor for disease progression. All BE patients undergo acid suppressive therapy, surveillance, and BE removal by surgery or endoscopic ablation, yet the incidence of EAC continues to increase. Despite the known side effects and mortality, the one-size-fits-all approach is the standard clinical management as there are no reliable methods for risk stratification.Methods: Paired-end Illumina NextSeq500 RNA sequencing was performed on total RNA extracted from 20-week intervals (0, 20, 40, and 60 W) of an in vitro BE carcinogenesis (BEC) model to construct time series global gene expression patterns (GEPs). The cells from two strategic time points (20 and 40 W) based on the GEPs were grown for another 20 weeks, with and without further acid and bile salt (ABS) stimulation, and the recurrent neoplastic cell phenotypes were evaluated.Results: Hierarchical clustering of 866 genes with ≥ twofold change in transcript levels across the four time points revealed maximum variation between the BEC20W and BEC40W cells. Enrichment analysis confirmed that the genes altered ≥ twofold during this window period associated with carcinogenesis and malignancy. Intriguingly, the BEC20W cells required further ABS exposure to gain neoplastic changes, but the BEC40W cells progressed to malignant transformation after 20 weeks even in the absence of additional ABS.Discussion: The transcriptomic gene expression patterns in the BEC model demonstrate evidence of a clear threshold in the progression of BE to malignancy. Catastrophic transcriptomic changes during a window period culminate in the commitment of the BE cells to a “point of no return,” and removal of ABS is not effective in preventing their malignant transformation. Discerning this “point of no return” during BE surveillance by tracking the GEPs has the potential to evaluate risk of BE progression and enable personalized clinical management.
Highlights
Esophageal adenocarcinoma (EA) is a morbid cancer with less than 15% 5-year survival (Eloubeidi et al, 2003; Polednak, 2003)
Using a mathematical algorithm and RNA-seq datasets from time series samples collected every 20 weeks (0, 20, 40, and 60 W) from a previously described Barrett’s epithelium (BE) carcinogenesis (BEC) model (Das et al, 2011), we demonstrate gene expression patterns (GEPs) coinciding with the progressive neoplastic changes in the non-neoplastic human Barrett’s epithelial cells (BAR-T) due to prolonged intermittent acid and bile salt (ABS) exposure
This suggests that the transcriptome of BEC20W is more similar to BEC0W cells and that of the BEC40W is more similar to BEC60W cells, and the major transcriptomic changes in the BEC model occurred in the window period between the BEC20W and BEC40W
Summary
Esophageal adenocarcinoma (EA) is a morbid cancer with less than 15% 5-year survival (Eloubeidi et al, 2003; Polednak, 2003). GERD is strongly implicated in the development of specialized columnar metaplasia or Barrett’s epithelium (BE) at the junction of the distal esophagus and the stomach (Lagergren et al, 1999; Hofstetter et al, 2001). This specialized tissue, BE, is a known precursor of EA, posing a 30- to 120-fold higher risk compared with the non-BE population (Wild and Hardie, 2003). Esophageal adenocarcinoma (EA) arises from Barrett’s epithelium (BE), and chronic gastroesophageal reflux disease is considered the strongest risk factor for disease progression. Despite the known side effects and mortality, the one-size-fits-all approach is the standard clinical management as there are no reliable methods for risk stratification
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
